Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients
NCT01215734
Completed
Hypothesis 1: The safety profile in adult allogeneic stem cell hematopoietic transplant (SCT) recipients after high dose (HD) trivalent inactivated influenza vaccine (TIV) will not be significantly different from adult stem cell transplant recipients receiving standard dose (SD) TIV. * Specific Aim 1: To compare safety profile of high dose trivalent inactivated influenza vaccine to standard dose trivalent inactivated influenza vaccine in adult hematopoietic stem cell transplant recipients. Hyp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2013
Locations: Vanderbilt-Ingram Cancer Center, Clinical Trials Information Program, Nashville, Tennessee
Conditions: Adult Stem Cell Hematopoetic Transplant
Register for Updates
Tetravalent Chimeric Dengue Vaccine Trial
NCT01110551
Completed
The purpose of this study is to test the safety and immune response to a live attenuated dengue vaccine that could protect people against all 4 types of dengue virus. Live attenuated means that while this vaccine contains 4 live dengue viruses the viruses have been attenuated (weakened) so as not to cause dengue disease in people. Dengue virus is spread to people by mosquitoes and can cause sickness and even death. Seventy-two subjects between the ages of 18-45 years old will be enrolled in this... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
01/31/2013
Locations: Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri
Conditions: Dengue
Register for Updates
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
NCT00028496
Completed
Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may make tumor cells more sensitive to the vaccine and may kill more tumor cells
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2013
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Gallbladder, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Male Breast Cancer, Mixed Adenocarcinoma of the Stomach, Ovarian Endometrioid Adenocarcinoma, Paget Disease of the Breast With Intraductal Carcinoma, Paget Disease of the Breast With Invasive Ductal Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Salivary Gland Adenocarcinoma, Stage II Malignant Testicular Germ Cell Tumor, Stage II Pancreatic Cancer, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Gallbladder Cancer
Register for Updates
Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)
NCT00005039
Terminated
Randomized phase II trial to determine the effectiveness of vaccine therapy in treating patients who have advanced adenocarcinoma of the prostate (prostate cancer). Vaccines made from a person's prostate cancer cells may make the body build an immune response to kill tumor cells
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/23/2013
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Register for Updates
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
NCT00030693
Terminated
Randomized phase I trial to compare the effectiveness of two different vaccines given directly into the tumor in treating patients who have metastatic solid tumors. Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a tumor may cause a stronger immune response and kill more tumor cells. It is not yet known which vaccine may be more effective in treating metastatic solid tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2013
Locations: Mount Sinai Medical Center, New York, New York
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
NCT00054041
Completed
Vaccines made from antigens may make the body build an immune response to kill abnormal cervical cells and may be effective in preventing cervical cancer. Randomized phase II trial to study the effectiveness of vaccine therapy in preventing cervical cancer in patients who have cervical intraepithelial neoplasia
Gender:
FEMALE
Ages:
17 years and above
Trial Updated:
01/23/2013
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3, Human Papilloma Virus Infection
Register for Updates
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
NCT00003023
Completed
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody A1G4 with BCG may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody A1G4 plus BCG in treating patients with cancer.
Gender:
ALL
Ages:
All
Trial Updated:
01/17/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Neuroblastoma, Sarcoma
Register for Updates
Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
NCT00373958
Completed
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal vaccine (13vPnC) compare to the 7-valent pneumococcal vaccine (7vPnC) and to compare the immune response to concomitant vaccines administered with 13vPnC and 7vPnC.
Gender:
ALL
Ages:
Between 42 days and 98 days
Trial Updated:
01/17/2013
Locations: Not set, Fayetteville, Arkansas +36 locations
Conditions: Vaccines, Pneumococcal
Register for Updates
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis
NCT01482052
Completed
The purpose of this study is to evaluate the safety of a new conjugate vaccine, NmVac4-A/C/Y/W-135-DT, compared to the safety of a similar, licensed meningococcal A/C/Y/W-135-DT conjugate vaccine. The investigators will also evaluate the production of antibodies to of NmVac4-A/C/Y/W-135-DT™ conjugate vaccine compared to the licensed vaccine, as a measure of vaccine effectiveness.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
01/11/2013
Locations: Kings Cardiology Group, Hanford, California
Conditions: Meningococcal Meningitis, Meningococcal Infections
Register for Updates
Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia
NCT00100971
Terminated
RATIONALE: Vaccines made from a person's white blood cells and cancer cells may make the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with acute myeloid leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/03/2013
Locations: Cancer Research Center at Boston Medical Center, Boston, Massachusetts
Conditions: Leukemia
Register for Updates
Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus
NCT00919178
Completed
Infection with dengue viruses is one of the leading causes of hospitalization and death in children in several tropical Asian counties. The World Health Organization (WHO) estimates that these viruses are responsible for more than 50 million cases of dengue fever (DF) and approximately 0.5 million cases of the more severe disease, dengue hemorrhagic fever/ shock syndrome (DHF/DSS) annually. Because dengue viruses are endemic in most tropical and subtropical regions, keeping more than 2 billion p... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/31/2012
Locations: Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland +1 locations
Conditions: Dengue Shock Syndrome, Dengue Hemorrhagic Fever
Register for Updates
Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine
NCT01072786
Completed
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. This study will evaluate the safety and immune responses of five formulations of a tetravalent dengue virus vaccine in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/31/2012
Locations: Center for Immunization Research, Johns Hopkins School of Public Health, Washington, District of Columbia +3 locations
Conditions: Dengue
Register for Updates